News
Rocket Pharmaceuticals Inc (NASDAQ:RCKT) on Tuesday announced an update related to RP-A501, its investigational gene therapy ...
The U.S. FDA has paused a mid-stage gene therapy trial by Rocket Pharmaceuticals after a patient suffered serious ...
Key Takeaways Rocket Pharmaceuticals halted a study of a gene-therapy drug for Danon disease because a patient had a "Serious ...
The FDA has slapped a clinical hold on Rocket Pharmaceuticals’ pivotal gene therapy trial in response to a death. Rocket, ...
A patient in a Rocket Pharmaceuticals gene therapy trial for a rare heart condition has died, the company said.
The FDA has placed a clinical hold on the study while Rocket works with trial monitors and experts to investigate the cause ...
Rocket Pharmaceuticals (RCKT) stock faces a 62% stock drop after FDA's hold on the company's Phase 2 gene therapy trial for ...
Jefferies analyst Andrew Tsai downgraded Rocket Pharmaceuticals from Buy to Hold and lowered the price target from $29 to ...
Barclays analysts downgraded CoreWeave (CRWV) to Equal Weight, raising valuation concerns. This is CoreWeave's first ...
FDA places clinical hold of RP-A501 for the treatment of patients with Danon disease due to a patient death. Click here to ...
A patient has died in a clinical trial evaluating a Rocket Pharmaceuticals gene therapy shortly after complications emerged that led the FDA to pause the study. An inquiry into the fatality is ...
The U.S. FDA has paused Rocket Pharmaceuticals' mid-stage gene therapy trial after a patient died from serious complications, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results